NEWS & PRESS
Meet Rachel Thu Nguyen and Sebastian Bruno Kleeberg at the NutrEvent in Rennes, France
Oct 17-18, 2023
Rachel will present the future of precision biotransformation in a five-minute pitch to potential investors. Together with Sebatian, she will be also available at the eversyn booth to answer all your questions about eversyn’s unique technology for nutrition and biopharma 🚀
Meet Dr. Thomas Rexer and Dr. Karim Jaen at the Festival of Biologics in Basel, Switzerland
Oct 10-12, 2023
🚀 Karim is set to unveil our Glycoengineering Toolbox, maximizing control over glycosylation for your biologics.
Meet Rachel Thu Nguyen and Dr. Volker Landschütze at Future Food Tech in London
Sep 28-29, 2023
Rachel who manages the business development of eversyn will present the future of precision biotransformation in a three-minute pitch to potential investors. Rachel & Volker (eversyn's CEO) will be also available at the eversyn booth to answer all your questions about eversyn’s unique technology for nutrition and biopharma 🚀
eversyn appoints Dr. Ing. Volker Landschütze as new interim CEO
Jul 19, 2023
eversyn today announced the appointment of Dr. Ing. Volker Landschütze as its Chief Executive Officer, following an intensive talent search supported by Max Planck Innovation. For the first time since founded, eversyn has its first CEO.
eversyn at the FASEB Human Milk Conference
Jun 4, 2023
This FASEB Science Research Conference (SRC) will explore the novel findings on human milk composition and bioactive function. Participants for this meeting will be principal scientists from various sectors who are interested in the breast milk area of research.
eversyn to present at the GlycoBioTec2023
June 7, 2022
Our whole team will be present in person at the GlycoBioTec 2023. We are looking forward to meeting you at our booth in the exhibition hall. Moreover, we will present our technology with a talk at the conference. Stay tuned for more information.
Grant of over 0.9 Mio € to develop our technology & business
January 1, 2022
We are delighted to announce that our team is supported by an Exist research transfer grant over 0.9 Mio € from the Federal Ministry for Economics and Climate Action. eversyn will use the proprietary, cost-efficient and highly scalable technology for the synthesis of nucleotide sugars and valuable oligosaccharides.